Last updated: April 28, 2026
Genentech, Inc. v. Biogen MA Inc. (D. Mass.) | 1:23-cv-11573: Litigation Status, Patent-Case Posture, and Commercial Impact
What is the case and where is it filed?
- Parties: Genentech, Inc. (plaintiff) v. Biogen MA Inc. (defendant)
- Court / Docket: U.S. District Court for the District of Massachusetts, Case No. 1:23-cv-11573
- Caption shown in docket filings: “Genentech, Inc. v. Biogen MA Inc.”
What claims and patent issues are litigated?
No actionable, claim-level information is provided in the available record in this session. The docket number is known, but the patents asserted, claim construction positions, accused product(s), and infringement theories are not included in the materials available here.
What procedural posture does the case have (motions, schedule, hearings)?
No actionable, docket-level procedural timeline is provided in the available record in this session. Without the underlying filings (complaint, answers, claim charts, motion practice, scheduling orders), the litigation posture cannot be stated with specificity.
What are the likely patent-infringement themes in Genentech vs. Biogen MA litigation generally?
Not determinable from the provided record. Genentech and Biogen-related patent disputes may span antibodies, biologics manufacturing, composition claims, method-of-use claims, or process claims, but the specific asserted patents and theories in 1:23-cv-11573 cannot be derived from the information present here.
What is the business risk for Genentech and Biogen MA based on the litigation structure?
Not determinable from the provided record. Without the asserted patent families, remaining life, claim scope, and the accused product and launch timeline, it is not possible to quantify:
- exposure to injunction or damages,
- probability-weighted settlement value,
- or the effect on Biogen’s commercialization plans.
What is the patent landscape impact if asserted patents have remaining enforceability?
Not determinable from the provided record. A credible landscape impact requires at least:
- asserted patent numbers (and continuations),
- expiration dates,
- prosecution history (priority, terminal disclaimer, reexamination),
- and whether the asserted claims are composition, formulation, method, or process.
Case-Readout Table (What can be stated from the provided record only)
| Item |
Value |
Source in record |
| Case caption |
Genentech, Inc. v. Biogen MA Inc. |
Provided docket reference |
| Court |
U.S. District Court for the District of Massachusetts |
Provided docket reference |
| Docket |
1:23-cv-11573 |
Provided docket reference |
| Plaintiff |
Genentech, Inc. |
Provided docket reference |
| Defendant |
Biogen MA Inc. |
Provided docket reference |
| Patents asserted |
Not provided |
Not present in provided record |
| Accused product |
Not provided |
Not present in provided record |
| Key motions |
Not provided |
Not present in provided record |
| Trial/claim schedule |
Not provided |
Not present in provided record |
| Injunction/damages posture |
Not provided |
Not present in provided record |
Key Takeaways
- Docket identified: Genentech, Inc. v. Biogen MA Inc., 1:23-cv-11573 in the District of Massachusetts.
- No claim-level or procedural specifics are available in the provided record here, so litigation posture (motions, schedule, asserted patents, infringement theories, and relief sought) cannot be stated with accuracy.
FAQs
-
What court is handling Genentech v. Biogen MA (1:23-cv-11573)?
U.S. District Court for the District of Massachusetts.
-
What is the case number?
1:23-cv-11573.
-
Who are the parties?
Genentech, Inc. (plaintiff) and Biogen MA Inc. (defendant).
-
Which patents are asserted?
Not stated in the provided record.
-
What stage is the case in?
Not stated in the provided record.
References
[1] Provided docket reference: “Genentech, Inc. v. Biogen MA Inc., 1:23-cv-11573 (D. Mass.).”
